ArticleScientific reports2026
Association between recombinant human growth hormone therapy and refractive status in Korean children with idiopathic short stature: a cross-sectional study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the association between recombinant human growth hormone (rhGH) therapy and ocular biometric and refractive characteristics in Korean children with idiopathic short stature (ISS). This cross-sectional study compared ocular parameters between children receiving rhGH therapy for ISS (GH group) and age- and sex-matched healthy controls. Comprehensive ophthalmologic assessments were performed, including axial length (AL), spherical equivalent refraction (SER), peripapillary retinal nerve fiber layer (pRNFL), and ganglion cell-inner plexiform layer (GC-IPL) thickness. The GH group showed significantly more myopic SER than controls (-1.68 ± 1.68 D vs. - 1.15 ± 1.17D, p = 0.048). Although mean AL was slightly longer in the GH group, the difference was not statistically significant (23.65 ± 1.10 mm vs. 23.43 ± 0.98 mm, p = 0.290). Sectoral pRNFL analysis revealed temporal thickening (p < 0.001) in the GH group. In multivariable analyses within the GH group, longer treatment duration was significantly associated with more myopic SER (P = 0.009). Although treatment duration was also associated with longer AL in the primary model (P = 0.041), this association became attenuated after exclusion of age from the model (P = 0.249). Exploratory analyses additionally demonstrated significant associations between thinner GC-IPL thickness and both more myopic SER (P = 0.010) and longer AL (P = 0.029) in the GH group. RhGH therapy in children with ISS was associated with more myopic refraction and distinct ocular structural characteristics in this cross-sectional analysis. The association between longer rhGH treatment duration and more myopic SER may suggest a possible relationship between prolonged rhGH exposure and refractive status. These findings should be interpreted cautiously, and further longitudinal studies are needed to clarify the long-term relationship between rhGH exposure and ocular growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.